secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001437749-23-005594
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic completes dosing in Phase 1 COVID-19 vaccine trial; no SAEs, Q2 data update expected
--------------------------------------------------------------------------------

- DYAI-100 COVID-19 booster vaccine trial: dosing of low and high dose groups completed Feb 2023.
- No serious adverse events reported; vaccine well tolerated to date.
- Initial safety and antibody response update expected in Q2 2023.
- First human test of C1-cell platform for vaccines; CEO notes increased interest from academia/industry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923005594/0001437749-23-005594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923005594/dyai20230306_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-005594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer